By Chris Wack

Galera Therapeutics said Thursday that the U.S. Food and Drug Administration has granted orphan drug designation to its second product candidate, rucosopasem manganese, for the treatment of pancreatic cancer.

Rucosopasem is a next-generation selective dismutase mimetic in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with pancreatic cancer and lung cancer.

The company is currently conducting a Phase 2b 220-patient trial of rucosopasem in combination with SBRT in patients with locally advanced pancreatic cancer.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

May 18, 2023 08:29 ET (12:29 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Galera Therapeutics (NASDAQ:GRTX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Galera Therapeutics 차트를 더 보려면 여기를 클릭.
Galera Therapeutics (NASDAQ:GRTX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Galera Therapeutics 차트를 더 보려면 여기를 클릭.